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Background: Advances in surgical technique, prosthetic heart valve design, and anticoagulation have contributed
to an overall improvement in morbidity and mortality in women with heart valve prostheses as well as increased
feasibility of pregnancy. Previous work investigating the pregnancies of women with prosthetic valves has been
directed largely toward understanding the influence of anticoagulation regimen. There has been little investigation
on maternal and infant outcomes. The objective of this systematic review will be to assess the outcomes of
pregnancy in women with heart valve prostheses in contemporary populations.
Methods/Design: A systematic search of Medline, Embase, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), and the Cochrane Library will be undertaken. Article titles and abstracts will be evaluated by
two reviewers for potential relevance. Studies that include pregnancies occurring from 1995 onwards and where
there are six or more pregnancies in women with heart valve prostheses included in the study population will be
reviewed for potential inclusion. Primary outcomes of interest will be mortality (maternal and perinatal). Secondary
outcomes will include other pregnancy outcomes. No language restrictions will be applied. Methodological quality
and heterogeneity of studies will be assessed. Data extraction from identified articles will be undertaken by two
independent reviewers using a uniform template. Meta-analyses will be performed to ascertain risk of adverse
events and, where numbers are sufficient, by type of prosthesis and location as well as other subgroup analyses.
Discussion: Estimates of the risk of adverse events in recent pregnancies of women with heart valve prosthesis
will provide better information for counselling and decision making. Given the improvements in prognosis of heart
valve prosthesis recipients and the paucity of definitive data regarding optimal pregnancy management for these
women, review of this topic is pertinent.
Review registration: This protocol has been registered with the international prospective register of systematic
reviews (PROSPERO) as number CRD42013006187, accessible online at http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42013006187#.Utk7qNJ9Lf8.Background
The etiology of valvular heart disease and management
of congenital heart disease in young women continues
to change. Advances in surgical technique, prosthetic
heart valve design, and anticoagulation have contributed
to an overall improvement in morbidity and mortality
[1-4]. The number of women with heart valve prostheses
counselled explicitly against pregnancy is decreasing
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reproduction in any medium, provided the orand cardiac parameters constitute high risk of adverse
events during pregnancy [5,6]. The focus is shifting to
provision of informed decision making around the risk
pregnancy might place on women and their babies. With
these changes in mind, understanding the outcomes of
pregnancies in women who have heart valve prostheses
in the contemporary setting is of increasing relevance.
During normal pregnancy, there is an increase in
hemodynamic load, which continues to rise during labor.
This is as a result of increases in stroke volume and heart
rate, increasing cardiac output by an estimated 30% to
40%, combined with a decrease in total peripheral resist-
ance, leading to a decrease in blood pressure [7-9]. Preg-
nancy is a pro-coagulant state due to an elevation inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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leading to decreases in prothrombin time, activated partial
thromboplastin time, thrombin time, and international
normalized ratio (INR) [10,11]. Tolerance of these hemo-
dynamic and coagulatory changes in women with pre-
existing heart disease, including those with bioprosthetic
and mechanical heart valve prostheses, is known to vary
with underlying cardiac function and etiology of cardiac
disease [6].
Previous work surrounding heart valve prostheses in
pregnancy has been largely directed toward understand-
ing the influence of anticoagulation type in the setting of
mechanical heart valve prostheses [12-16]. A systematic
review published in 2000, including 976 women who
had 1,234 pregnancies, focused on maternal and fetal
complications associated with various anticoagulation reg-
imens [17]. The review included studies with pregnancies
occurring from 1966 to 1997. As such, a large number of
study participants (433/976) had older-generation and
more thrombogenic cage-and-ball heart valve prostheses.
Pooled analysis from this work demonstrated higher rates
of fetal malformation in those women treated with oral
anticoagulation in the first trimester (6.4%, confidence
interval (CI) 95% 4.6%-8.9%, of pregnancies) as compared
with where heparin was used in the first trimester (3.4%,
CI 95% 1.4%-7.7%, of pregnancies) [17]. A higher risk of
thromboembolic complications was noted with heparin
use. Another more recent review (2011) using pooled
data from 959 pregnancies receiving oral anticoagulation
throughout pregnancy and 285 pregnancies receiving
unfractionated heparin in the first trimester found an inci-
dence of maternal thromboembolic complications in 3.9%
and 9.5% of pregnancies in each group, respectively [15].
In the setting of mechanical heart valve prostheses in
pregnancy, there is consensus in current international
guidelines that one of three anticoagulation regimens
may be used following assessment of maternal risk fac-
tors and preference: oral anticoagulation throughout
pregnancy, oral anticoagulation with replacement by
low-molecular-weight heparin or unfractionated heparin
during weeks 6 to 12, or low-molecular-weight heparin
or unfractionated heparin throughout pregnancy. Each
of these regimens requires counseling around risk and
judicious monitoring throughout, including INR and anti-
factor Xa levels where applicable [5,18,19]. The Royal
College of Obstetricians recommends that women be
offered a choice of one of these three regimens with edu-
cation around the risks and benefits of each [20].
Bioprosthetic heart valves avoid the need for anticoa-
gulation during pregnancy [19,21]. However, their use in
younger patients has previously been limited due to the
increased need for re-replacement compared with their
mechanical counterparts [22,23]. This has been demon-
strated in young women specifically, with 82% (CI 95%62%-92%) of women with bioprosthetic valve prostheses
requiring replacement at 10 years as opposed to only
29% (CI 95% 17%-39%) of women with mechanical
valves [22]. Despite initial suggestions, recent work has not
shown an increase in the rate of bioprosthetic valve deteri-
oration in women undertaking pregnancies as opposed to
women who do not [24,25]. With decreasing mortality and
morbidity associated with valve re-replacement, interna-
tional guidelines suggest that bioprosthetic valves be consi-
dered when heart valve replacement is required in women
who may wish to become pregnant [5,26].
Little work has been done exploring the population of
contemporary heart valve recipients undertaking preg-
nancy. Specifically, other than anticoagulant type [12-17],
there has been little investigation around rates and risk
factors for maternal and infant adverse events. Given the
changes in heart valves used, improvement in prognosis of
contemporary heart valve prosthesis recipients, and the
paucity of data in regarding the outcomes of pregnancies
in these women, review of the studies in this area is
warranted.
Objectives
Primary: To assess the risks of adverse outcomes of
pregnancy among women with a prosthetic heart valve
(s) in the contemporary setting.
Secondary: To assess the risks and relative risks of ad-
verse outcomes of pregnancy in women with a prosthetic
heart valve(s) by prosthesis type or location or both.
Methods/Design
Study registration
This protocol has been registered with the international
prospective register of systematic reviews (PROSPERO)
as number CRD42013006187.
The systematic review protocol has been conducted
and reported by using the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
[27] where applicable and the Meta-analysis of Obser-





2) Any pregnancy lossa. Any loss of pregnancy, including
miscarriage/stillbirth/termination of
pregnancy [29] (or as defined by study)
3) Perinatal mortality [29]
a. Stillbirth: Fetal death in utero at
least 22 weeks of gestation [29]
(or as defined by the study)
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extra-uterine life [29]
c. Perinatal mortality: Stillbirth or neonatal
mortalitySecondary outcomes:
1) Adverse maternal outcomes
a. Any thromboembolic events, including
i. Stroke/Transient ischemic event
ii. Valve thrombosis
iii. Other
b Any obstetric hemorrhage, including
i. Antenatal hemorrhage
ii. Postpartum hemorrhage
c. Cardiovascular compromise (as defined by study)
d. Valve deterioration (bioprosthetic valves only,




h. Pregnancy hypertension, including
gestational hypertension, pre-eclampsia,
and eclampsia
2) Labor and delivery outcomes (including those
subject to clinical decision making)
a. Mode of delivery
3) Adverse birth outcomes
a. Preterm birthDelivery before 37 weeks of gestation
b. Small for gestational age
Less than tenth birth weight percentile for
sex and gestational age
c. Low birth weight
Birth weight less than 2,500 grams
d. Infant admission to neonatal intensive
care unit
e. Congenital malformationSearch strategy for identification of studies and methods
of review
A systematic search of Medline, Embase, Cumulative
Index to Nursing and Allied Health Literature (CINAHL),
and the Cochrane Library will be undertaken to identify
relevant studies published between 1995 and May 2013.
Search terms will include “pregnancy” AND (“heart
valves” OR “heart valve replacement” OR “heart valve
prosthesis” OR “heart valve prosthesis implantation”). The
“explode” function will be used in each case. Searches will
be limited to studies of humans and peer-reviewed
articles. Language restrictions will not be applied, and
every effort will be made to obtain translations; articles
unable to be translated will be reported. Duplicates
will be removed.Eligibility criteria for consideration of inclusion
Study types:
Studies that report outcomes of women with prosthetic
valves undertaking pregnancy:




 Unselected case series
Studies that compare outcomes for women with pros-
thetic valves by valve location or type:




Control or comparison groups are not necessary to the
primary objective of estimating risk among women with
valve prosthesis. It is anticipated that most of the studies
identified for consideration will be case series.
Populations: Populations of pregnant women that in-
clude women with prosthetic heart valves.
Comparators:
Where studies differentiate between mechanical and
biological valve prosthesis, or between valve location
(that is, mitral, aortic, pulmonary, and tricuspid), applic-
able to the secondary objective; relative risks by prosthesis
type or location or both, relative risks of adverse events
will be calculated by using:
 Biological prosthesis as the denominator for
calculating relative risk compared with mechanical
 Presence of mitral valve prosthesis as the
denominator for calculating relative risk compared
with other valve locations
Study criteria:
 Include pregnancies occurring from 1995
onwards only.
 Contain at least six pregnancies in women with
heart valve prostheses in the study population.
This was chosen as it has been used in a
systematic review exploring anticoagulation
regimens during pregnancy in women with
heart valve prostheses [17].
 Study population should have fewer than 5% of
women with a Starr-Edwards (cage-and-ball) heart
valve prosthesis. This was a pragmatic decision.
Owing to high thrombogenic complication rates,
cage-and-ball prostheses are no longer implanted
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evaluating in the contemporary setting.
Consequently, where the study population
consists of not more than 20 women, if one
(5%) or more participants has a cage-and-ball
valve, the study will be excluded.
 Where a case series is presented, participants have
not been selected due to the occurrence of an
adverse event (for example, valve thrombosis
during pregnancy).
 Not a conference abstract and unpublished study.
Exposure of interest: Pregnancy in women with a heart
valve prosthesis.
Screening of studies
Article titles and abstracts will be evaluated by two
reviewers for potential relevance. Where there is dis-
agreement at this stage, the article will remain included
until the full text is reviewed prior to a decision. In this
process, articles relating to other aspects of valvuar heart
disease and pregnancy but not specific to maternal
vavular prostheses will be excluded (for example, articles
related to fetal cardiac disease or basic science). Articles
identified through reference lists of included studies and
relevant systematic reviews will be considered for inclu-
sion on the basis of their title.
At least two independent reviewers will assess all
articles identified in the screening process for potential
inclusion, including assessment of methodological qual-
ity as outlined below. Where information pertinent to
inclusion criteria is not contained within the article text,
the effort will be made to contact the listed correspond-
ing author. Where no reply is received, the article will
be excluded. Consensus between the two authors under-
taking review of the study will need to be reached before
the article is included. In the event that a consensus is
not reached, a third reviewer will be involved as an
arbitrator. A flow chart of the study selection pro-
cedure will be prepared and a log of rejected studies
maintained.
Data extraction
Data extraction from identified articles will be under-
taken by two independent reviewers using a uniform
template. Discrepancies will be resolved by discussion
and, where applicable, arbitration by a third reviewer.
The following information will be extracted:
Study characteristics: authors, year of publication,
study design, location, and time period of included
pregnancies
Population characteristics: number of participants,
number of pregnancies, maternal age, and parityHeart valve characteristics: number of mechanical
valves, number of bioprosthetic valves, implanted
valve type, implanted valve location, and
anticoagulation regimen
Adverse outcomes: frequency of adverse outcomes
as outlined above.
Assessment of methodological quality
It is thought likely that the only randomized studies
eligible for inclusion will be randomized control trials
assessing different valve types. The risk of bias in ran-
domized studies will be assessed by using the Cochrane
Collaboration’s tool for assessing risk of bias [32]. This
tool provides a model to evaluate the risk of bias across
a number of domains: how a study selects participants,
measures performance, blinds participants and investi-
gators, explores attrition, and reports findings. Each do-
main for each study will be allocated a ranking of “low”,
“unclear”, or “high” risk of bias, in accordance with the
Cochrane Collaboration’s approach, by two separate re-
viewers. Where there is a discrepancy between the two
reviewers, a third reviewer will be used as an arbitrator.
Included non-randomized studies may or may not
have a comparison group. To assess the risk of bias
within included these studies, the methodological quality
of potential studies will be assessed by using the
Newcastle-Ottawa scale (NOS) for assessing the quality
of non-randomized studies in meta-analyses [33]. The
NOS for case–control and cohort studies will be adapted
(Table 1) to meet the specific needs of this systematic
review. The cohort scale will be modified for use in case
series [33]. Using the NOS, studies will be awarded a
maximum of nine points on items related to the selec-
tion of the study groups, the comparability of the
groups, and the ascertainment of outcome of interest.
Using this modified score, case series will be eligible for
a maximum of six points. This will be undertaken by
two separate reviewers. Where there is disagreement, a
third reviewer will be used as an arbitrator.
Data analysis and presentation
A table with descriptive information for each study will
be produced Additional file 1: Table S1. From extracted
data, the risk of outcomes for the primary objective will
be calculated by dividing the total number of outcome
occurrences by the total number of pregnancies or births
to women with a heart valve prosthesis. The risk of ma-
ternal mortality and any pregnancy loss will be expressed
as the proportion of the total number of pregnancies
(including miscarriages, terminations, stillbirths, and live
births). The risk of perinatal death and secondary adverse
birth outcomes (as opposed to pregnancy outcomes) will
be expressed as a proportion of the pregnancies beyond
22 weeks of gestation or 500 grams or resulting in a live
Table 1 Adapted Newcastle-Ottawa scale [33] for
“Prosthetic heart valves in pregnancy: a systematic




1) Representativeness of the exposed cohort
a) Population truly representative of pregnant
women with prosthetic heart valves
★
b) Somewhat representative of the population
of pregnant women with prosthetic heart
valves
★
c) Selected group of users (for example,
referral hospital patients)
-
d) No description of the derivation of
the cohort
-
2) Selection of the non-exposed cohortb
a) Drawn from the same community as
the exposed cohort
★
b) Drawn from a different source -
c) No description of the derivation of the
non-exposed cohort
-
d) Not applicable -
3) Ascertainment of exposure
a) Secure record (for example,
medical records)
★
b) Structured interview ★
c) Written self-report -
d) No description -




c) Not applicable -
Comparability
Comparability of cohorts on the basis of the design or analysis
a) Study controls for maternal age (select the
most important factor)
★
b) Study controls for any additional
factor (type of valve, valve location,
anticoagulation regimen)
★
c) Not applicable -
Outcome
1) Assessment of outcome
a) Independent blind assessment ★
b) Record linkage ★
c) Self-report -
d) No description -




Table 1 Adapted Newcastle-Ottawa scale [33] for
“Prosthetic heart valves in pregnancy: a systematic
review and meta-analysis protocol” (Continued)
3) Adequacy of follow up of cohorts
a) Complete follow up (all subjects accounted
for and no missing data)
★
b) Subjects lost to follow-up unlikely to
introduce bias - small number lost - ≥ 80%
★
c) Follow-up rate < 80% -
d) No statement -
aA study can be awarded a maximum of one star for each numbered item
within the selection and outcome categories. A maximum of two stars can be
given for comparability. bFor example, women without a heart valve prosthesis
undertaking pregnancy. Likely to be “not applicable” for some study types,
including case series. cSuggested primary outcomes: maternal mortality, any
pregnancy loss, and perinatal mortality.
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not always be clearly articulated, potentially constraining
the process to what is reported in each study.
Subgroup analysis of primary and secondary outcome
relative risks by valve location and valve type will be
undertaken if reported by at least two studies, each with
at least six pregnancies in the subgroup. Comprehensive
Meta-Analysis (version 2.0) software (Biostat, Englewood,
NJ, USA) be used for the data analysis. This software en-
ables pooling of risks as well as of relative risks, making it
suitable for our primary objective, especially as it is anti-
cipated that the majority of studies will be case series.
Pooled risks will be calculated by using a random effects
model, with variance calculated by using a logit conver-
sion. Graphic summaries of individual study estimates and
overall estimates will be produced. Statistical uncertainty
will be assessed by using 95% confidence intervals around
risk estimates.
Where applicable, heterogeneity of effect for studies
within a meta-analysis will be assessed with the I2
statistic. Study heterogeneity will be explored by cate-
gorization of the study design, the year of publication, the
time period within which pregnancies occur, and popu-
lation characteristics (ethnicity, age range, etiology of
underlying disease, type and location of heart valve
prosthesis, and anticoagulant regimen). It is expected
that study characteristics will vary and that random
effects models will be appropriate for estimating over-
all event risks.
In general, the strength of evidence will be assessed
with respect to the study designs, the methodological
quality of the individual studies, the consistency of the
results across studies, and, for studies with a comparison
or control group, the strength of associations. More
specifically, given the likelihood that most studies will be
uncontrolled case series, the strength of evidence will be
assessed primarily by the width of the confidence inter-
val around pooled outcome rates. Consistency of effect
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the plots and as quantified by the I2 statistic.Discussion
Improved care for chronic diseases and delayed age of
childbearing has contributed to an increase in the num-
ber of pregnant women with concurrent medical condi-
tions, including valvular heart disease. The proposed
systematic review is of importance in the context of
global pressure to improve maternal and infant health,
including the evaluation of pregnancies in subgroups of
women with co-morbidities. In Australia, this is seen
through the prioritization of research work encompassing
“Healthy start to life for all Australians” [20].
Meta-analyses of observational studies present chal-
lenges because of inherent biases within different study
designs [34]. Nevertheless, they help understanding and
quantify variation in results between studies [28]. In the
context of predominantly observational studies, it is thus
essential that a rigorous protocol be designed to address
the outcome of pregnancies in women with heart valve
prostheses.
Through exploration of the outcomes of pregnancies
in women with heart valve prosthesis in the contem-
porary setting (1995 onwards), this systematic review
will provide estimates of the risk of adverse events in
these pregnancies. It is hoped that this information will
improve the understanding of risk factors for poor ma-
ternal, pregnancy, and infant outcomes, thereby provid-
ing information for clinical decision making and patient
counselling. It is timely that this work is undertaken
given the developments in heart valve prosthesis technol-
ogy, overall improvement in prognosis of young women
with a heart valve prosthesis, and increases in the number
of women with congenital heart disease reaching repro-
ductive age.Additional file
Additional file 1: Table S1. Sample of table to record descriptive
information extracted from each included study.Abbreviations
CI: confidence interval; INR: international normalized ratio; NOS: Newcastle-
Ottawa scale.
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